Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Orchestra BioMed Holdings (OBIO) EPS (Weighted Average and Diluted): 2022-2024

Historic EPS (Weighted Average and Diluted) for Orchestra BioMed Holdings (OBIO) over the last 3 years, with Dec 2024 value amounting to -$1.66.

  • Orchestra BioMed Holdings' EPS (Weighted Average and Diluted) rose 2.44% to -$0.40 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.82, marking a year-over-year decrease of 13.04%. This contributed to the annual value of -$1.66 for FY2024, which is 12.16% down from last year.
  • According to the latest figures from FY2024, Orchestra BioMed Holdings' EPS (Weighted Average and Diluted) is -$1.66, which was down 12.16% from -$1.48 recorded in FY2023.
  • Orchestra BioMed Holdings' EPS (Weighted Average and Diluted)'s 5-year high stood at -$1.48 during FY2023, with a 5-year trough of -$2.24 in FY2022.
  • For the 3-year period, Orchestra BioMed Holdings' EPS (Weighted Average and Diluted) averaged around -$1.79, with its median value being -$1.66 (2024).
  • As far as peak fluctuations go, Orchestra BioMed Holdings' EPS (Weighted Average and Diluted) skyrocketed by 33.93% in 2023, and later dropped by 12.16% in 2024.
  • Yearly analysis of 3 years shows Orchestra BioMed Holdings' EPS (Weighted Average and Diluted) stood at -$2.24 in 2022, then spiked by 33.93% to -$1.48 in 2023, then dropped by 12.16% to -$1.66 in 2024.